1 fda perspective sally loewke, m.d. acting division director division of medical imaging and...
TRANSCRIPT
![Page 1: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/1.jpg)
1
FDA Perspective
Sally Loewke, M.D.
Acting Division Director
Division of Medical Imaging and Radiopharmaceutical Drug Products
CDER/FDA
February 3 & 4, 2003
![Page 2: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/2.jpg)
2
Use of Imaging Drugs in Conjunction with Cardiac Imaging
Procedures in the Pediatric Population
![Page 3: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/3.jpg)
3
Outline
• Draft Guidance
• Approved cardiac indications
• Extrapolation
• Pediatric Drug Use Trends
• Safety data
• Focus of today
![Page 4: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/4.jpg)
4
FDA• Regulatory Agency• 6 Centers
– CDER: Center for DRUGS– CBER: Center for BIOLOGICS– CDRH: Center for DEVICES and Radiologic Health – CVM: Center for VETERINARY MEDICINE– CFSAN: Center for FOODS– NCTR: National Center of Toxicologic Research
![Page 5: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/5.jpg)
5
CDER Mission
CDER assures that safe and effective drugs are available to the American people
![Page 6: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/6.jpg)
6
Division of Medical Imaging and Radiopharmaceutical Drug Products
• Office of New Drugs
• Regulates medical imaging drugs
– Contrast agents
– Radiopharmaceuticals
![Page 7: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/7.jpg)
7
Contrast Agent
• Medical imaging agent used to improve the visualization of tissues, organs and physiologic processes by increasing the relative difference of imaging signal intensities in adjacent regions of the body
• Examples: Iodinated agents, Gadolinium, Microspheres
![Page 8: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/8.jpg)
8
Diagnostic Radiopharmaceutical
• An article that is intended for use in the diagnosis or monitoring of a disease or a manifestation of a disease in humans and that exhibits spontaneous disintegration of unstable nuclei with the emission of nuclear particles or photons
• Any radioactive reagent kit or nuclide generator that is intended to be used in the preparation of such an article
![Page 9: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/9.jpg)
9
Draft GuidanceDeveloping Medical Imaging Drug and
Biologic Products
• Current Agency thinking
• Indications
– Structure delineation
– Disease or pathology detection or assessment
– Functional, physiological, or biochemical assessment
– Diagnostic or therapeutic patient management
![Page 10: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/10.jpg)
10
New Drug ApplicationsClinical Assessment
Components of a Clinical Review for New Drug Applications– Efficacy
• Dose• Pharmacokinetics• Clinically relevant endpoints• Relevant patient population• Appropriate standard of truth
– Safety• Identification of major toxicities• Adverse Event profile
– Risk/Benefit Assessment determines approval
![Page 11: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/11.jpg)
11
Labeled Cardiac Indications by Drug Class
Drug Class and
Approved Indication
Adult Approval
Pediatric
Approval
Iodinated ContrastAngiography √ √
Gadolinium
RadiopharmaceuticalsMyocardial Perfusion (ischemia) √Myocardial Function √
MicrospheresEndocardial Border Delineation √
![Page 12: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/12.jpg)
12
Shift in Perception Regarding Pediatric Requirements
– Historically: Assumption that children were little adults
– 1970s: Change in thinking
– Today: Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act
![Page 13: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/13.jpg)
13
Extrapolation
If the course of disease and the effects of the drug are similar in adults and pediatric patients
THEN FDA may conclude that pediatric efficacy can be extrapolated from adequate and well- controlled studies in adults, usually supplemented with other information obtained in pediatric patients, such as pharmacokinetic and safety studies
![Page 14: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/14.jpg)
14
Extrapolation When may it not be appropriate?
• Disease is different in etiology, pathophysiology and/or manifestations
• Response to therapy is different
• Pathophysiology may be comparable but response to therapy not predictably the same in adults and children
• Pharmacokinetic parameters are not well-defined in adults
![Page 15: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/15.jpg)
15
ExtrapolationIs it possible for cardiac disease?
• Differences in the pathophysiology of cardiac disease
– Pediatrics: congenital heart disease
– Adults: atherosclerotic heart disease
• Do differences in etiology and pathophysiology affect imaging drug performance?
![Page 16: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/16.jpg)
16
Pediatric Use TrendsChild Health Corporation of America’s (CHCA)
Pediatric Health Information System (PHIS) DatabaseInpatient data from 31 free-standing Children’s hospitals with charge
level drug utilization dataStrengths– First access to pediatric inpatient drug use data– Children’s hospitals provide information on off-label useLimitations– No national projections available– FDA has drug data beginning in 1999– No direct link between drug and diagnosis/procedure
– Does not capture outpatient use & free standing imaging centers – Contrast media or radiopharmaceuticals are usually bundled together
with the imaging procedure and can not be specifically identified.
![Page 17: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/17.jpg)
* represents undercount of actual use 17
Drug class Drug Mentions
in pediatric patients
(0-16 years)
2001
Drug Mentions
in pediatric patients
(0-16 years)
2002
Iodinated contrast 8,782 10,170
Gadolinium contrast 2,724 2,873
Radiopharmaceuticals 3 5
Microspheres 1 2
Total Discharges 245,125 258,621
CHCA PHIS Database*
![Page 18: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/18.jpg)
18
Pediatric Safety Data
• Limited knowledge based on few approvals
• Adverse Event Reporting System (AERS)
– Spontaneous and voluntary
• underreporting
• reporting bias
• quality of report
• cannot estimate true incidence rate of events or exposure risk
![Page 19: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/19.jpg)
19
AERS Search • Methodology
– Selected specific drugs per drug class
– Combined results
– Most common AEs reported (10% of total or greater)
– Deaths
– Search timeframe variable- based on approval dates
![Page 20: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/20.jpg)
20
Adverse Events (AERS)Iodinated Contrast Agents (2 drugs)
• ADULTS
– >16-95 years
– Timeframe: 1986-2003
– N=2997 reports
– Common Event Types
• Pruritus
• Dermatitis
• Urticaria
– Deaths: 274
• PEDIATRICS
– 0 - ≤ 16 years
– Timeframe: 1986-2003
– N= 68 reports
– Common Event Types
• Urticaria
• Dyspnea
• Facial edema
– Deaths: 2
![Page 21: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/21.jpg)
21
Adverse Events (AERS)Gadolinium* (2 drugs)
• ADULTS– >16-95 years– Timeframe: 1988-2003– N= 5,163 reports– Common Event Types
• Urticaria• Vomiting• Nausea• Dyspnea• Pruritus
– Deaths: 108* No approved cardiac indication
• PEDIATRICS– 0 - ≤ 16 years– Timeframe: 1988-2003– N= 233 reports– Common Event Types
• Vomiting• Nausea• Urticaria
– Deaths: 3
* No approved cardiac indication
![Page 22: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/22.jpg)
22
Adverse Events (AERS) Radiopharmaceuticals (2 drugs)
• ADULTS– >16-95 years– Timeframe: 1988-2004– N= 334 reports– Common Event Types
• Dermatitis• Pruritus• Urticaria• Nausea• Cough• Headache• Dyspnea
– Deaths: 16
• PEDIATRICS
– 0 - ≤ 16 years
– Timeframe:1988-2004
– N= 0 reports
– Common Event Types None
– Deaths: 0
![Page 23: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/23.jpg)
23
Adverse Events (AERS)Microspheres (2 drugs)
• ADULTS– >16-95 years
– Timeframe: 1998-2003
– N= 107 reports
– Common Event Types• Back pain
• Headache
– Deaths: 0
• PEDIATRICS– 0 - ≤ 16 years
– Timeframe: 1998-2003
– N= 0 reports
– Common Event Types None
– Deaths: 0
![Page 24: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/24.jpg)
24
Conclusions
• Few approvals in the pediatric population
• Limited use data
• Limited safety data
• Differing cardiac disease processes
![Page 25: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/25.jpg)
25
Questions for the Panel1. Given the differences in cardiac disease processes that occur in adults
and children, in what cases (if any) can adult data from approved imaging drugs be extrapolated to pediatric patients in whom cardiac imaging is needed? If so, in what cardiac disease states?
2. If further studies in pediatric patients are needed, please further define the gaps in our knowledge regarding imaging agents to be evaluated for cardiac imaging applications by discussing the following questions:
– What imaging agents need further study?
– What populations should be studied?
– What disease states should be studied?
– What endpoints should be used?
– How should a trial be designed?
– How should the standard for comparison be defined? Is there a gold-standard?
![Page 26: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/26.jpg)
26
Questions for the Panel
3. Please discuss the relevance of new developments in the field of adult cardiac imaging that may have potential application to the pediatric population? Can we anticipate the need for future drug development for pediatric cardiac imaging?
![Page 27: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/27.jpg)
27
Focus• Imaging drugs
• Is there need for additional drug labeling?
– How are these drugs being used in pediatrics?
• For what purpose?
• In what subpopulations?
• How do the imaging results impact management?
– Is extrapolation possible?
![Page 28: 1 FDA Perspective Sally Loewke, M.D. Acting Division Director Division of Medical Imaging and Radiopharmaceutical Drug Products CDER/FDA February 3 & 4,](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649d305503460f94a0865e/html5/thumbnails/28.jpg)
28
THANK YOU